Although there is no direct evidence that CASP3 regulates lipid metabolism, our scrutiny of the in vitro NAFLD model in this investigation established up-regulated CASP3 expression in NAFLD, which was reversed by treatment with CSEE. Here, CASP3 is linked to metabolic dysfunction-associated steatotic liver disease.